REG3A and graft versus host disease: In a study using this 2 biomarker with severe GVHD by Hartwell and colleagues, they showed that patients with high ST2 and Reg3 levels had higher 6-month mortality, and that the combination of these two biomarkers could be a predictive test for nonrelapse mortality [10].